Filing Flows › Syndax Pharmaceuticals (SNDX) › Q2 2025
Syndax Pharmaceuticals (SNDX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 4, 2025
Syndax Pharmaceuticals (SNDX) reported revenue of $38.0M for the second quarter 2025 (Q2 2025), +985% from a year earlier and +89% from the quarter before. Operating margin was -182.7%, net loss $71.8M (189.3% of revenue).
Syndax Pharmaceuticals, Q2 2025: revenue $38.0M (+984% year over year), operating margin -182.7%, net loss $71.8M, operating cash flow −$87.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $38.0M | +89% | +985% |
| Operating profit | −$69.4M | — | — |
| Net earnings | −$71.8M | — | — |
| Operating cash flow | −$87.8M | — | — |
What changed
Revenue was $38.0M in Q2 2025, up 985% year over year and up 89% from the previous quarter. Product was the largest line at 75% of revenue.
Operating costs exceeded revenue by $69.4M, an operating margin of -182.7%. Total costs grew 38% against revenue growth of 985%. The fastest-growing cost line was General & admin (+51%). The quarter ended with a net loss of $71.8M, narrower than the previous quarter's $84.8M loss.
Operating cash flow was −$87.8M. Non-cash charges added back $13.8M of share-based compensation. Working capital and other items used $29.7M.
Questions
What was Syndax Pharmaceuticals' revenue in the second quarter 2025?
Syndax Pharmaceuticals (SNDX) reported revenue of $38.0M for the second quarter 2025 (Q2 2025), +985% from a year earlier and +89% from the quarter before.
Was Syndax Pharmaceuticals profitable in the second quarter 2025?
Operating loss was $69.4M (-182.7% of revenue) and net loss $71.8M.